Tradestie Institutional Equity Comparison Engine

BEAM vs MRNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MRNA Overall Edge

MRNA Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BEAM trades at N/M Forward P/E with -267.7% operating margin (-96.8% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, BEAM sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
BEAM N/M vs MRNA 23.0x Fwd P/E
Growth & Margin Winner MRNA
Op Margin -267.7% vs -80.8% ยท YoY -96.8% vs +29.2%
Momentum & Technical Winner MRNA
1Y -0.4% vs +706.5% ยท 52W Pos 4% vs 67%
Options & Structure Winner MRNA
BREAKDOWN (34th %ile IV) vs CONSOLIDATION (52nd %ile IV)
BEAM NASDAQ
Beam Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$20.90
-0.19% 1D
Market Cap $2.2B
1M Return -14.9%
1Y Return -0.38%
Forward P/E N/M
Unified AI Score
60.3 / 100 BUY
Tech 70.0 Fund 66.0 Flow 67.0 Mom 60.0
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
1M Return -3.77%
1Y Return +706.45%
Forward P/E 23.0x
Unified AI Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BEAM -0.38% MRNA +706.45% Spread: +706.83 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period BEAM Revenue MRNA Revenue BEAM Op. Margin MRNA Op. Margin Margin Edge
FY2018 N/A $140M N/A -306.0% MRNA
FY2019 $0M $60M -417522.2% -906.8% MRNA
FY2020 $0M $800M -553166.7% -95.0% MRNA
FY2021 $50M $18.5B -757.0% 72.0% MRNA
FY2022 $60M $19.3B -555.6% 48.9% MRNA
FY2023 $380M $6.85B -46.7% -61.9% BEAM
FY2024 $60M $3.24B -654.3% -121.9% MRNA
FY2025 $140M $1.94B -274.6% -158.1% MRNA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BEAM (3) vs MRNA (7)
Institutional Metric BEAM MRNA Criterion Row Winner
Market Capitalization Scale $2.2B $80.7B Larger Scale MRNA
Trailing P/E Ratio Valuation N/M 23.0x Lower Multiple MRNA
Forward P/E Ratio Valuation N/M 23.0x Lower Multiple MRNA
Revenue Growth (YoY) Growth -96.8% +29.2% Higher Growth MRNA
Operating Margin (TTM) Profitability -267.7% -80.8% Higher Margin MRNA
Net Profit Margin Profitability -73.9% -110.5% Higher Margin BEAM
Return on Equity (ROE) Capital Efficiency -11.3% -34.5% Higher ROE BEAM
52-Week Range Position Momentum 4% ($20โ€“$38) 67% ($22โ€“$281) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 2.09ฮฒ ยท 86% Vol 2.23ฮฒ ยท 78% Vol Lower Realized Risk MRNA
Unified Institutional Score Composite Signal 60.3 / 100 (BUY) 40.3 / 100 (SELL) Higher Composite BEAM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BEAM vs MRNA Buy Guide
BEAM BREAKDOWN
107d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 34th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live BEAM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BEAM nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.